In 2022, an estimated 11·7 million people were affected by chronic hepatitis C virus (HCV) infection in the WHO Eastern Mediterranean Region (EMR), accounting for 23% of the global burden.1 This ...

Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.

Screening, vaccination and destigmatisation are essential to eliminating a disease that affects 29 million Indians ...

Viral diseases called hepatitis B and C primarily target the liver and often incubate quietly for decades before any symptoms ...

In a pair of articles published in Lancet Gastroenterology & Hepatology, scientists lay out the case for why we should expand ...

A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, ...

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...

After rabies pre-exposure prophylaxis (PrEP) vaccination, scarcely available rabies immunoglobulins are not required for post-exposure prophylaxis (PEP). However, PrEP is not sufficiently accessible ...

In a recent paper published in Science Translational Medicine, scientists report that a class of drugs, called RNA interference (RNAi) therapeutics, represent a major advancement in the treatment of ...

We read with great interest the recent article by Tseng et al evaluating hepatitis B surface antigen (HBsAg) levels as a ...